Discover our Pipeline Products
Dermagnostix is the Solution for the Challenges in Dermatology
Dermagnostix addresses these challenges as a visionary in molecular diagnostics in dermatology, pioneering a new era in patient care. Our innovative pipeline, featuring LymphX, PatternX and PsorX 2.0, delivers targeted, efficient diagnostic solutions tailored for labs and clinics. These products empower precise diagnosis and personalized treatment decisions by analyzing patients' molecular profiles directly on-site. Dermagnostix’s fully automated, user-friendly solutions optimize time and resources for healthcare professionals, setting a new standard in precision dermatology for a future-focused approach to patient care.
Supports clinicans through characterization & stratification of patients with inflammatory skin diseases according to molecular patterns.
Sampling method: Biopsy/FFPE samples
This Dermagnostix gene expression-based test will enable the differential diagnosis of mycosis fungoides (MF), psoriasis, and eczema. Accurate and early diagnosis is needed to improve patients’ quality of life and overall life expectancy.
Sampling method: Biopsy/FFPE samples
Molecular test to support the differential diagnosis of psoriasis, eczema and tinea. Covers most frequent causes for red scaly skin lesions at the Point-of-Care.
Sampling method: Minimal-invasive sampling (scraping/tape)
LymphX
Detection of Early-Stage Mycosis Fungoides versus Benign Inflammatory Skin Diseases
LymphX, a gene expression-based test, will enable the differential diagnosis of mycosis fungoides (MF), psoriasis, and eczema. Accurate and early diagnosis is needed to improve patients’ quality of life and overall life expectancy.
The most common form of cutaneous t-cell lymphoma (CTCL), mycosis fungoides (MF), is a malignant tumor of the skin that often manifests as red Patches resembling benign inflammatory dermatoses. In particular in its early stages, MF mimics psoriasis or eczema, making clinical and histopathological diagnosis challenging. Latest data highlight: 35% of patients diagnosed with MF or Sézary syndrome had previously been diagnosed as AD or psoriasis.¹
“The diagnosis of early MF (patch stage) is particularly challenging […] This diagnosis might be elusive because MF in its early stage shares clinical and histopathological features with inflammatory benign dermatoses…and immunohistochemistry and molecular analysis have limited utility as isolated criteria." 2
¹n=4 million, Zech IM, et al. ADO-Kongress 2024, Würzburg; Abstract #eP134. 2. Howles A, et al. Br J Hosp Med (Lond) 2021;82:1–6.
2Torres-Cabala CA (2020): Diagnosis of T-cell lymphoid proliferations of the skin: putting all the pieces together. Modern Pathology 33:83-95.
PatternX
Stratification of Patients with Inflammatory Skin Diseases According to Molecular Patterns
PatternX identifies inflammatory disease markers, characterizes endotypes, and supports companion and complementary diagnostics development, as well as patient stratification and selection in clinical research.
There is a need for timely and cost-efficient identification of molecular biomarkers in research and clinical development to inform target selection, drug candidate selection and to understand the mechanism of action. Biomarkers are valuable tools for drug discovery and development.
"Utilization of biomarkers has a potential to make dug discovery, development, and approval processes more efficient"
Gromova M, et al. (2020): Biomarkers: opportunities and challenges for drug development in the current regulatory landscape. Biomarker Insights 15: 1177271920974652.
PsorXD
Differential Diagnosis of Psoriasis and Eczema for the Point-of-Care.
PsorXD will analyze tissue samples obtained through minimal-invasive methods, such as tape strips or curettes. This will enable dermatologists to use the test directly in their office at the Point-of-Care, which will make the results available even more quickly in the highest molecular biological quality.
More Dermagnostix Products
LabDisk-Analyzer
The LabDisk-Analyzer is a modular diagnostic system designed to process all current and future Dermagnostix LabDisks. With advanced microfluidic technology, it provides dermatopathologists and dermatologists with the scalability to efficiently conduct even rare molecular tests. This system minimizes manual errors, boosts efficiency, and accelerates the introduction of pipeline innovations, such as tests for mycosis fungoides or biomarker-based inflammation patterns.
PsorX-LabDisk
The PsorX-LabDisk represents a breakthrough in dermatological diagnostics as the first molecular test for distinguishing psoriasis from eczema. It works seamlessly with the LabDisk-Analyzer, offering fully automated and precise gene expression analysis. As part of Dermagnostix's innovative pipeline, the PsorX-LabDisk sets a benchmark for personalized treatment decisions, addressing unmet clinical needs in dermatopathology. With our molecular tests, you enhance trust and confidence in clinical decisions!
By loading the video, you agree to YouTube's privacy policy.
Learn more
Shaping the Future of Dermatology Together!
Looking for dermatopathology labs using molecular diagnostics?
Find PsorX partner labs near you!
Explore our international network of PsorX partner labs or contact us for more.